Literature DB >> 3494039

Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies.

J Björkander, L Hammarström, C I Smith, R H Buckley, C Cunningham-Rundles, L A Hanson.   

Abstract

Sera from three hundred five patients with immunoglobulin deficiencies were analyzed for the presence of anti-IgA antibodies by using indirect agglutination and enzyme-linked immunosorbent assay (ELISA). Anti-IgA antibodies were observed in 15 of 68 (22%) patients with hypogammaglobulinemia and 53 of 185 (29%) patients with selective IgA deficiency, both groups having serum IgA less than 0.05 g/liter. The highest frequency, 6 of 10 or 60%, was noted for patients with a combined IgA-IgG2 deficiency. No anti-IgA antibodies were detected in 25 patients with serum IgA between 0.05 and 0.27 g/liter and normal amounts of serum IgM and IgG or in 17 patients with hypogammaglobulinemia who had serum IgA of 0.05-0.7 g/liter. The anti-IgA antibodies were primarily of the IgG class, but IgD and IgM anti-IgA were occasionally found. IgE anti-IgA antibodies could not be detected with the presently used technique. The IgG anti-IgA antibodies were mainly of the IgG1 subclass but occasionally also of the subclasses IgG2, IgG3, and IgG4. Of eight patients with anti-IgA antibodies, seven tolerated Ig prophylaxis with a commercial immunoglobulin preparation low in IgA when given either intramuscularly or intravenously. The titers of anti-IgA in the sera of these patients did not rise in relation to the prophylaxis. Only one of the eight patients had a history of previous anaphylactic reactions to IgA-containing blood products. He tolerated six Ig infusions during 5 months with the IgA-depleted preparation without any adverse effects but showed increasing levels of anti-IgA antibodies and ultimately experienced a near-fatal reaction at the seventh infusion.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3494039     DOI: 10.1007/BF00915419

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  27 in total

1.  Anaphylactic reactions to plasma infusions in patients with hypogammaglobulinemia and anti-IgA antibodies.

Authors:  J V Wells; R H Buckley; M S Schanfield; H H Fudenberg
Journal:  Clin Immunol Immunopathol       Date:  1977-09

2.  Anti-IgA antibodies of limited specificity in healthy IgA deficient subjects.

Authors:  J Koistinen; R M Cardenas; H H Fudenberg
Journal:  J Immunogenet       Date:  1977-10

3.  Chromic chloride: a coupling reagent for passive hemagglutination reactions.

Authors:  E R Gold; H H Fudenberg
Journal:  J Immunol       Date:  1967-11       Impact factor: 5.422

4.  Anaphylactoid transfusion reactions associated with anti-IgA.

Authors:  G N Vyas; H A Perkins; H H Fudenberg
Journal:  Lancet       Date:  1968-08-10       Impact factor: 79.321

5.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

6.  IgG4: a possible mediator of anaphylaxis in a haemophiliac patient.

Authors:  F Shakib; D R Stanworth
Journal:  Clin Allergy       Date:  1979-11

7.  Selective IgA deficiency in Rh-negative women.

Authors:  M K Pai; M Davison; I Bedritis; A Zipursky
Journal:  Vox Sang       Date:  1974       Impact factor: 2.144

8.  Family studies in individuals with selective absence of gamma-A-globulin.

Authors:  J B Natvig; M Harboe; O Fausa; A Tveit
Journal:  Clin Exp Immunol       Date:  1971-02       Impact factor: 4.330

9.  Human antibodies to immunoglobulin A (IgA). A radioimmunological method for differentiation between anti-IgA antibodies and IgA in the serum of IgA deficient individuals.

Authors:  P J Van Munster; J H Nadorp; H J Schuurman
Journal:  J Immunol Methods       Date:  1978       Impact factor: 2.303

10.  Evidence of persistent IgA/IgG circulating immune complexes associated with activation of the complement system in serum of a patient with common variable immune deficiency: anaphylactic reactions to intravenous gammaglobulin.

Authors:  V Wahn; R A Good; S Gupta; S Pahwa; N K Day
Journal:  Acta Pathol Microbiol Immunol Scand Suppl       Date:  1984
View more
  25 in total

Review 1.  Adverse effects of intravenous immunoglobulin therapy.

Authors:  U E Nydegger; M Sturzenegger
Journal:  Drug Saf       Date:  1999-09       Impact factor: 5.606

Review 2.  How I treat common variable immune deficiency.

Authors:  Charlotte Cunningham-Rundles
Journal:  Blood       Date:  2010-03-23       Impact factor: 22.113

Review 3.  [Intravenous immunoglobulins in chronic idiopathic myositis].

Authors:  H Michels; G-R Burmester; F Buttgereit
Journal:  Z Rheumatol       Date:  2005-03       Impact factor: 1.372

4.  The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy.

Authors:  H M Chapel; G P Spickett; D Ericson; W Engl; M M Eibl; J Bjorkander
Journal:  J Clin Immunol       Date:  2000-03       Impact factor: 8.317

5.  Long-term follow-up of anti-IgA antibodies in healthy IgA-deficient adults.

Authors:  S Koskinen; H Tölö; M Hirvonen; J Koistinen
Journal:  J Clin Immunol       Date:  1995-07       Impact factor: 8.317

Review 6.  Intravenous immunoglobulin in neurology--mode of action and clinical efficacy.

Authors:  Jan D Lünemann; Falk Nimmerjahn; Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2015-01-06       Impact factor: 42.937

7.  Anti-IgA antibodies in IgA-deficient children.

Authors:  F H Sennhauser; C S Hosking; C L Jones; R A MacDonald; N Mermelstein; D M Roberton
Journal:  J Clin Immunol       Date:  1988-09       Impact factor: 8.317

Review 8.  Intravenous immune globulin in primary immunodeficiency.

Authors:  M Haeney
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

9.  Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin.

Authors:  V M Brennan; N J Salomé-Bentley; H M Chapel
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

10.  Long-term use of IgA-depleted intravenous immunoglobulin in immunodeficient subjects with anti-IgA antibodies.

Authors:  C Cunningham-Rundles; Z Zhou; S Mankarious; S Courter
Journal:  J Clin Immunol       Date:  1993-07       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.